Physiogenex
  • About Us
    • Company overview
    • Management Team
    • Our values
    • Facilities
    • Partners
  • CRO Services
    • Obesity – Insulin Resistance – Diabetes
    • NASH – Fibrosis
    • Diabetic Nephropathy
    • Fibrosis
    • Diabetic Neuropathy
    • GLP-1 Expertise
    • Immunometabolism
    • Dyslipidaemia Atherosclerosis
    • Nutraceuticals
    • Covid-19
  • Capabilities
    • In vivo metabolic studies
    • Ex vivo metabolic assays
    • Biochemical assays and histology analysis
    • Biological samples library
  • Consulting
  • Publications
  • News
  • careers
    • Spontaneous Application
    • Careers at Physiogenex
  • Contact us
Select Page
Sort By ID
Filter Categories
Filter - All
Cardiovascular diseases
Diabetes - Obesity
Dyslipidemia
NASH - Liver disease
Nutraceuticals
Diabetic Nephropathy
Imaging
  • Nephropathy in diabetic db/db mice is accelerated by high protein diet and improved by the SGLT2 inhibitor dapagliflozin.
    09/27/2019
    Oct 05 2019
    Nørgaard SA, Briand F, Sand FW, Galsgaard ED, Søndergaard H, Sørensen DB, Sulpice T.
    READ MORE
  • Anacetrapib and dalcetrapib
    05/06/2019
    Eur J Pharmacol. 2014 October;740: 135–143.
    Briand F, Thieblemont Q, Muzotte E, Burr N, Urbain I, Sulpice T, Johns DG.
    READ MORE
  • Evaluation of Antiatherogenic Properties of Ezetimibe Using 3H-Labeled Low-Density-Lipoprotein Cholesterol and 99mTc-cAbVCAM1-5 SPECT in ApoE-/- Mice Fed the Paigen Diet 2017
    05/06/2019
    NCBI
    Briand F,  Burr N, Urbain I, Mayoux E, Sulpice T.
    READ MORE
  • Probiotic B420 and prebiotic polydextrose improve efficacy of antidiabetic drugs in mice.
    09/22/2015
    Diabetol Metab Syndr. 2015 Sep; 12; 7:75.
    Stenman L.K,  Waget A,  Garret C, Briand F,  Burcelin R, Sulpice T, Lahtinen S.
    READ MORE
  • Liraglutide improves hepatic steatosis and metabolic dysfunctions in a 3-week dietary mouse model of non-alcoholic steatohepatitis.
    11/25/2013
    World Diabetes Congress, December 2-6, 2013. Melbourne, Australia.
    Duparc T, Briand F, Trenteseaux C, Mérian J, Combes G, Najib S, Sulpice T, Martinez L, .
    READ MORE
  • Obeticholic acid raises LDL-cholesterol and reduces HDL-cholesterol in the Diet-Induced NASH (DIN) hamster model.
    01/05/2018
    NCBI, Jan 05, 2018.
    Briand F, Brousseau E, Quinsat M, Burcelin R, Sulpice T.
    READ MORE
  • Contribution of leukocyte infiltration to lipoperoxidation occurring in the non-ischemic region of the rat heart submitted to permanent left coronary artery occlusion
    05/24/2012

    Sulpice T, Boucher F, Pucheu S, de Leiris J.

    READ MORE
  • Limiting lipid peroxidation in the nonischemic zone of infarcted rat hearts by indomethacin improves left ventricular function without affecting myocardial healing and remodeling
    05/24/2012

    Sulpice T, Boucher F, de Leiris J.

    READ MORE
  • EUK-8 a synthetic catalytic scavenger of reactive oxygen species protects isolated iron-overloaded rat heart from functional and structural damage induced by ischemia/reperfusion
    05/24/2012
    Cardiovasc Drugs Ther. 1996 Jul;10(3):331-9.
    Pucheu S, Boucher F, Sulpice T, Tresallet N, Bonhomme Y, Malfroy B, de Leiris J.
    READ MORE
  • Role of peripheral benzodiazepine receptors in mitochondrial, cellular, and cardiac damage induced by oxidative stress and ischemia-reperfusion
    05/24/2012
    J Pharmacol Exp Ther. 2003 Sep;306(3):828-37.
    Leducq N, Bono F, Sulpice T, Vin V, Janiak P, Fur GL, O'Connor SE, Herbert JM.
    READ MORE
  • New insights into the pathological role of TNF-alpha in early cardiac dysfunction and subsequent heart failure after infarction in rats
    05/24/2012
    Am J Physiol Heart Circ Physiol. 2004 Jul;287(1):H340-50.
    Berthonneche C, Sulpice T, Boucher F, Gouraud L, de Leiris J, O'Connor SE, Herbert JM, Janiak P.
    READ MORE
  • AT1 receptor blockade prevents cardiac dysfunction after myocardial infarction in rats
    05/24/2012
    Cardiovasc Drugs Ther. 2005 Aug;19(4):251-9.
    Berthonneche C, Sulpice T, Tanguy S, O'Connor S, Herbert JM, Janiak P, de Leiris J, Boucher F.
    READ MORE
  • Dietary-induced insulin resistance associated with dyslipidemia induces progressive cardiac dysfunction in rats as evidenced by echocardiocardiography
    05/24/2012
    Arch Cardiovasc Dis. 2009 Mar;102(S1):22.
    Grauzam S, Toufektsian MC, Ormezzano O, Jouan MG, Boucher F, Sulpice T.
    READ MORE
  • Cardiac dysfunction in rats with dietary-induced insulin resistance associated with pharmacologically-induced dyslipidemia.
    05/02/2013
    Curr Pharm Des. 2013;19(39):6906-11.
    Tanguy S, Toufektsian MC, Grauzam S, de Leiris J, Ghezzi C, Boucher F, Sulpice T.
    READ MORE
  • Berberine increases LDL-cholesteryl ester catabolism and stimulates LDL-derived cholesterol fecal excretion in hyperlipidemic hamsters.
    05/25/2012
    European Atherosclerosis Society Congress, May 25-28, 2012, Milan, Italy .
    Briand F, Thieblemont Q, Muzotte E , Sulpice T.
    READ MORE
  • Raising HDL with CETP inhibitor Torcetrapib improves insulin resistance and modulates in vivo tissue glucose uptake in dyslipidemic and insulin resistant hamsters.
    11/25/2013
    American Heart Association, November 16-20, 2013, Dallas, Texas, USA.
    Briand F, Thieblemont Q, Muzotte E, Sulpice T.
    READ MORE
  • Raising HDL with CETP inhibitor Torcetrapib improves glucose homeostasis in dyslipidemic and insulin resistant hamsters.
    03/24/2014
    DEUEL conference on Lipids, March 4 – 7, 2014, California, USA.
    Briand F, Prunet-Marcassus B, Thieblemont Q, Costard C, Muzotte E, Sulpice T.
    READ MORE
  • Ezetimibe prevents Atherogenesis ahrough increased catabolism and fecal excretion of LDL-cholesterol and reduced atherosclerotic plaque inflammation in ApoE knock-out mice fed a Paigen diet.
    06/16/2015
    ATVB, May 7-9, 2015, California, USA.
    Briand F, Dumas L.S, Broisat A, Ahmadi M, Bacot S, Devoogdt N, Riou L. M, Ghezzi C, Sulpice T.
    READ MORE
  • Metabolism of cholesterol ester of apolipoprotein B100-containing lipoproteins in dogs: evidence for disregarding cholesterol ester transfer.
    08/24/2004
    Eur J Clin Invest. 2004 Aug;34(8):527-34.
    Bailhache E, Briand F, Nguyen P, Krempf M, Magot T, Ouguerram K.
    READ MORE
  • Selective uptake of high density lipoproteins cholesteryl ester in the dog, a species lacking in cholesteryl ester transfer protein activity: an in vivo approach using stable isotopes.
    09/24/2004
    Comp Biochem Physiol B Biochem Mol Biol. 2004 Aug;138(4):339-45.
    Ouguerram K, Nguyen P, Krempf M, Pouteau E, Briand F, Bailhache E, Magot T.
    READ MORE
  • Effects of atorvastatin on high-density lipoprotein apolipoprotein A-I metabolism in dogs.
    04/24/2006
    Eur J Clin Invest. 2006 Apr;36(4):224-30.
    Briand F, Magot T, Krempf M, Nguyen P, Ouguerram K.
    READ MORE
  • Atorvastatin increases intestinal cholesterol absorption in dogs.
    07/24/2006
    J Nutr. 2006 Jul;136(7 Suppl):2034S-2036S.
    Briand F, Serisier S, Krempf M, Siliart B, Magot T, Ouguerram K, Nguyen P.
    READ MORE
  • Fenofibrate lowers lipid parameters in obese dogs.
    08/24/2006
    Nutr. 2006 Jul;136(7 Suppl):2037S-2040S.
    Serisier S, Briand F, Ouguerram K, Siliart B, Magot T, Nguyen P.
    READ MORE
  • Metabolism of high density lipoprotein apolipoprotein A-I and cholesteryl ester in insulin resistant dog: a stable isotope study.
    01/24/2007
    Diabetes Obes Metab. 2007 Jan;9(1):139-42.
    Briand F, Bailhache E, Nguyen P, Krempf M, Magot T, Ouguerram K.
    READ MORE
  • The hyperenergetic-fed obese dog, a model of disturbance of apolipoprotein B-100 metabolism associated with insulin resistance: kinetic study using stable isotopes.
    07/24/2008
    Metabolism. 2008 Jul;57(7):966-72.
    Briand F, Bailhache E, Andre A, Magot T, Krempf M, Nguyen P, Ouguerram K.
    READ MORE
  • Both the Peroxisome Proliferator-Activated Receptor Agonist, GW0742, and Ezetimibe Promote Reverse Cholesterol Transport in Mice by Reducing Intestinal Reabsorption of HDL-Derived Cholesterol.
    05/24/2009
    Clin trans Sci. 2009; 2:127-133.
    Briand F, Naik SU, Fuki I, Millar JS, Macphee C, Walker M, Billheimer J, Rothblat G, Rader DJ.
    READ MORE
  • The use of dyslipidemic hamsters to evaluate drug-induced alterations in reverse cholesterol transport.
    03/24/2010
    Curr Opin Investig Drugs. 2010 Mar;11(3):289-97.
    Briand F.
    READ MORE
  • Liver X receptor activation promotes macrophage-to-feces reverse cholesterol transport in a dyslipidemic hamster model.
    04/24/2010
    J Lipid Res. 2010 Apr;51(4):763-70.
    Briand F, Tréguier M, André A, Grillot D, Issandou M, Ouguerram K, Sulpice T.
    READ MORE
  • P2Y13 receptor is critical for reverse cholesterol transport.
    10/24/2010
    Hepatology. 2010 Oct;52(4):1477-83.
    Fabre AC, Malaval C, Ben Addi A, Verdier C, Pons V, Serhan N, Lichtenstein L, Combes G, Huby T, Briand F, Collet X, Nijstad N, Tietge UJ, Robaye B, Perret B, Boeynaems JM, Martinez LO.
    READ MORE
  • Modulation of HDL metabolism by the niacin receptor GPR109A in mouse hepatocytes.
    11/24/2010
    Biochem Pharmacol. 2010 Nov 1;80(9):1450-7.
    Li X, Millar JS, Brownell N, Briand F, Rader DJ.
    READ MORE
  • Biliary sterol secretion is required for functional in vivo reverse cholesterol transport in mice.
    03/24/2011
    Gastroenterology. 2011 Mar;140(3):1043-51.
    Nijstad N, Gautier T, Briand F, Rader DJ, Tietge UJ.
    READ MORE
  • Diet-induced dyslipidemia impairs reverse cholesterol transport in hamsters.
    09/24/2011
    Eur J Clin Invest. 2011 Sep;41(9):921-8.
    Tréguier M, Briand F, Boubacar A, André A, Magot T, Nguyen P, Krempf M, Sulpice T, Ouguerram K.
    READ MORE
  • Anacetrapib promotes reverse cholesterol transport and bulk cholesterol excretion in Syrian golden hamsters.
    11/24/2011
    J Lipid Res. 2011 Nov;52(11):1965-73.
    Castro-Perez J, Briand F, Gagen K, Wang SP, Chen Y, McLaren DG, Shah V, Vreeken RJ, Hankemeier T, Sulpice T, Roddy TP, Hubbard BK, Johns DG.
    READ MORE
  • An alternative method to measure in vivo reverse cholesterol transport in hyperlipidemic hamsters.
    12/10/2011
    Circulation. 2011; 124: A11835.
    Briand F, Thieblemont Q, Muzotte E, Sulpice T.
    READ MORE
  • CETP inhibitor Torcetrapib promotes reverse cholesterol transport in obese insulin-resistant CETP-ApoB100 transgenic mice.
    12/24/2011
    Clin Transl Sci. 2011 Dec;4(6): 414-420.
    Briand F, Thieblemont Q, André A, Ouguerram K, Sulpice T.
    READ MORE
  • Sitagliptin promotes macrophage-to-feces reverse cholesterol transport through reduced intestinal cholesterol absorption in obese insulin resistant CETP-apoB100 transgenic mice.
    01/24/2012
    Diabetes Obes Metab. 2012 Jul;14(7):662-5.
     Briand F, Thieblemont Q, Burcelin R, Sulpice T.
    READ MORE
  • High-fat and fructose intake induces insulin resistance, dyslipidemia, and liver steatosis and alters in vivo macrophage-to-feces reverse cholesterol transport in hamsters.
    05/24/2012
    J Nutr. 2012 Apr;142(4): 704-709.
    Briand F, Thieblemont Q, Muzotte E, Sulpice T.
    READ MORE
  • Upregulating reverse cholesterol transport with cholesteryl ester transfer protein inhibition requires combination with the LDL-lowering drug berberine in dyslipidemic hamsters.
    11/12/2012
    Arterioscler Thromb Vasc Biol. 2013 Jan;33(1):13-23.
    Briand F, Thieblemont Q, Muzotte E, Sulpice T.
    READ MORE
  • Raising HDL with CETP inhibitor Torcetrapib improves insulin resistance and modulates in vivo tissue glucose uptake in dyslipidemic and insulin resistant hamsters.
    01/28/2014
    Atherosclerosis. 2014 233:359-362.
    Briand F, Prunet-Marcassus B, Thieblemont Q, Costard C, Muzotte E, Sordello S, Sulpice T.
    READ MORE
  • Anacetrapib and dalcetrapib differentially alters HDL metabolism and macrophage-to-feces reverse cholesterol transport at similar levels of CETP inhibition in hamsters.
    07/07/2014
    Eur J Pharmacol. 2014 October;740: 135–143.
    Briand F, Thieblemont Q, Muzotte E, Burr N, Urbain I, Sulpice T, Johns DG.
    READ MORE
  • Inverse distribution of uncoupling proteins expression and oxidative capacity in mature adipocytes and stromal-vascular fractions of rat white and brown adipose tissues.
    05/24/1999
    FEBS Lett. 1999 Dec 31;464(3):184-8.
    Prunet-Marcassus B, Moulin K, Carmona MC, Villarroya F, Pénicaud L, Casteilla L.
    READ MORE
  • Evidence for a direct effect of melatonin on mitochondrial genome expression of Siberian hamster brown adipocytes.
    05/24/2001
    J Pineal Res. 2001 Mar;30(2):108-15.
    Prunet-Marcassus B, Ambid L, Viguerie-Bascands N, Pénicaud L, Casteilla L.
    READ MORE
  • Melatonin reduces body weight gain in Sprague Dawley rats with diet-induced obesity
    05/24/2003
    Endocrinology. 2003 Dec;144(12):5347-52.
    Prunet-Marcassus B, Desbazeille M, Bros A, Louche K, Delagrange P, Renard P, Casteilla L, Pénicaud L.
    READ MORE
  • Fenofibrate prevents Rosiglitazone-induced body weight gain in ob/ob mice
    05/24/2005
    Int J Obes. 2005 Jul;29(7):864-71.
    Carmona MC, Louche K, Nibbelink M, Prunet B, Bross A, Desbazeille M, Dacquet C, Renard P, Casteilla L, Pénicaud L.
    READ MORE
  • From heterogeneity to plasticity in adipose tissues: site-specific differences.
    05/24/2006
    Exp Cell Res. 2006 Apr 1;312(6):727-36.
    Prunet-Marcassus B, Cousin B, Caton D, André M, Pénicaud L, Casteilla L.
    READ MORE
  • Glucokinase activator PSN-GK1 displays enhanced antihyperglycaemic and insulinotropic actions.
    05/24/2007
    Diabetologia. 2007 Jun;50(6):1277-87.
    Fyfe MC, White JR, Taylor A, Chatfield R, Wargent E, Printz RL, Sulpice T, McCormack JG, Procter MJ, Reynet C, Widdowson PS, Wong-Kai-In P.
    READ MORE
  • Metabolic endotoxemia initiates obesity and insulin resistance.
    07/24/2007
    Diabetes. 2007 Jul;56(7):1761-72.
    Cani PD, Amar J, Iglesias MA, Poggi M, Knauf C, Bastelica D, Neyrinck AM, Fava F, Tuohy KM, Chabo C, Waget A, Delmée E, Cousin B, Sulpice T, Chamontin B, Ferrières J, Tanti JF, Gibson GR, Casteilla L, Delzenne NM, Alessi MC, Burcelin R.
    READ MORE
  • Adipose tissue sensitivity to radiation exposure.
    01/24/2009
    Am J Pathol. 2009 Jan;174(1):44-53.
    Poglio S, Galvani S, Bour S, André M, Prunet-Marcassus B, Pénicaud L, Casteilla L, Cousin B.
    READ MORE
  • Pharmacological inhibition of Stearoyl-CoA Desaturase 1 improves insulin sensitivity in insulin-resistant rat models.
    09/24/2009
    Eur J Pharmacol. 2009 Sep 15;618(1-3):28-36
    Issandou M, Bouillot A, Brusq JM, Forest MC, Grillot D, Guillard R, Martin S, Michiels C, Sulpice T, Daugan A.
    READ MORE
  • An adiponectin-like molecule with antidiabetic properties.
    10/24/2009
    Endocrinology. 2009 Oct;150(10):4493-501.
    Sulpice T, Prunet-Marcassus B, Molveaux C, Cani P, Vitte PA, Graber P, Dreano M, Burcelin R.
    READ MORE
  • La translocation de bactéries intestinales vers les tissus adipeux initie l’inflammation et le diabète induits par un régime gras chez la souris.
    03/24/2011
    Diabetes & Metabolism. 2011 Mar;37(1, S1):A7
    Chabo C, Amar J, Waget A, Klopp P, Vachoux C, Smirnova N, Bergé M, Sulpice T, Lahtinen S, Ouwehand A, Rautonen N, Sansonetti P, Burcelin R.
    READ MORE
  • Physiological and pharmacological mechanisms through which the DPP-4 inhibitor Sitagliptin regulates glycemia in mice.
    09/24/2011
    Endocrinology. 2011 Aug 15;2(8):3018-29.
    Waget A, Cabou C, Masseboeuf M, Cattan P, Armanet M, Karaca M, Castel J, Garret C, Payros G, Maida A, Sulpice T, Holst JJ, Drucker DJ, Magnan C, Burcelin R.
    READ MORE
  • Intestinal mucosal adherence and translocation of commensal bacteria at the early onset of type 2 diabetes: molecular mechanisms and probiotic treatment.
    09/28/2011
    EMBO Mol Med. 2011 Sep;3(9):559-72.
    Amar J, Chabo C, Waget A, Klopp P, Vachoux C, Bermúdez-Humarán LG, Smirnova N, Bergé M, Sulpice T, Lahtinen S, Ouwehand A, Langella P, Rautonen N, Sansonetti PJ, Burcelin R.
    READ MORE
  • Effect of the antipsychotic agent amisulpride on glucose lowering and insulin secretion.
    04/24/2012
    Diabetes Obes Metab. 2012 Apr;14(4):329-34.
    Roix JJ, Decrescenzo GA, Cheung PH, Ciallella JR, Sulpice T, Saha S, Halse R.
    READ MORE
  • Partial inhibition of adipose tissue lipolysis improves glucose metabolism and insulin sensitivity without alteration of fat mass.
    02/22/2013
    PLOS Biology. 2013 Feb;11(2).
    Girousse A, Tavernier G, Valle C, Moro C, Mejhert N, Dinel AL, Houssier M, Roussel B, Besse-Patin A, Combes M, Mir L, Monbrun L, Bézaire V, Prunet-Marcassus B.
    READ MORE
  • Cathepsin S inhibition lowers blood glucose levels in mice.
    06/13/2014
    Diabetologia. 2014 August; 57(8): 1674-1683.
    Lafarge JC, Pini M, Pelloux V, Orasanu G, Hartmann G, Venteclef N, Sulpice T, Shi GP, Clément K, Guerre-Millo M.
    READ MORE
  • Deletion of Apoptosis Signal-Regulating Kinase 1 (ASK1) Protects Pancreatic Beta-Cells from Stress-Induced Death but Not from Glucose Homeostasis Alterations under Pro-Inflammatory Conditions.
    12/15/2014
    PLoS One. 2014; 9(11):e112714.
    Pepin E, Higa A, Schuster-Klein C, Bernard C, Sulpice T, Guardiola B, Chevet E, Alquier T.
    READ MORE

Physiogenex is a preclinical CRO providing original and benchmarked animal models of obesity/type 2 diabetes and related co-morbidities: NASH/fibrosis, dyslipidemia, inflammation, diabetic nephropathy and cardiovascular complications. For > 15 years, we have been evaluating the drugs’ efficacy of our clients using gold-standard and radio-tracer based experiments in our validated preclinical models. Our customers benefit from our experience in drug development and expertise in metabolic diseases, as demonstrated with our numerous co-publications with our industry partners.

For more information on our company and offers, please download our Corporate Presentation.

Menu

  • CRO Services
  • Consulting
  • Publications
  • News
  • Careers

Services

  • Obesity – Diabetes
  • NASH Preclinical
  • Dyslipidaemia Atherosclerosis
  • Diabetic Nephropathy
  • Nutraceuticals

Useful Menu

  • Accueil
  • Contact us
  • Site map
  • Legal mentions
  • Privacy Policy

Contact

PHYSIOGENEX S.A.S.

Address : 280 rue de l’Hers, ZAC de la Masquère, 31750 Escalquens – France
Phone : +33532097980

For general inquiries, please contact us here.

  • Twitter
  • RSS
Copyright © PHYSIOGENEX
This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish.Accept Read More
Privacy & Cookies Policy

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may affect your browsing experience.
Necessary
Always Enabled
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Non-necessary
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.
SAVE & ACCEPT